The US~Observer, an investigative newspaper focused on exposing misconduct in government, finance and law enforcement, has published an article examining alleged market manipulation involving Quantum BioPharma Ltd. (QNTM). The publication reports that the allegations are part of a $700 million-plus lawsuit currently before the U.S. District Court for the Southern District of New York (Case No. 1:24-cv-07972), where claims of spoofing and related trading activity are under legal review.
According to the article by investigative reporter Michael Quiel, the investigation centers on Andrea Nalyzyty, CIBC’s chief compliance officer since at least 2015. The US~Observer writes that hundreds of alleged spoofing episodes involving millions of trading orders may have influenced the market for Quantum BioPharma shares, potentially depressing the company’s valuation during a period when it was advancing research on Lucid-MS, an experimental therapy targeting damage to nerve myelin associated with multiple sclerosis.
The article also outlines a series of regulatory penalties issued to CIBC entities during Nalyzyty’s tenure, including enforcement actions by Canadian and U.S. regulators related to supervisory, reporting and compliance failures. The US~Observer states that its investigation is part of its broader mission to examine financial misconduct and regulatory oversight issues that may affect investors, market integrity and companies seeking to fund medical innovation.
The implications of this investigation are significant. If the spoofing allegations are substantiated, it could represent a major breach of market integrity, potentially harming retail investors and undermining confidence in the capital markets. For Quantum BioPharma, a company focused on developing treatments for multiple sclerosis, such manipulation could have delayed critical funding for its research. Moreover, the involvement of a high-ranking compliance officer at a major bank raises questions about the effectiveness of internal controls and regulatory oversight. The case also highlights the ongoing challenges regulators face in detecting and prosecuting spoofing, a form of market manipulation that involves placing orders with the intent to cancel them before execution to create a false impression of supply or demand.
The US~Observer encourages individuals with additional information regarding market manipulation, spoofing, or related misconduct affecting Quantum BioPharma to contact them confidentially through their website at Uso.live.
